Publications

  1. Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial. Hepatology. 2025 May 16 [Epub ahead of print]
    View PubMed
  2. Goyal L, DiToro D, Facchinetti F, Martin EE, Peng P, Baiev I, Iyer R, Maurer J, Reyes S, Zhang K, Majeed U, Berchuck JE, Chen CT, Walmsley C, Pinto C, Vasseur D, Gordan JD, Mody K, Borad M, Karasic T, Damjanov N, Danysh BP, Wehrenberg-Klee E, Kambadakone AR, Saha SK, Hoffman ID, Nelson KJ, Iyer S, Qiang X, Sun C, Wang H, Li L, Javle M, Lin B, Harris W, Zhu AX, Cleary JM, Flaherty KT, Harris T, Shroff RT, Leshchiner I, Parida L, Kelley RK, Fan J, Stone JR, Uboha NV, Hirai H, Sootome H, Wu F, Bensen DC, Hollebecque A, Friboulet L, Lennerz JK, Getz G, Juric D. A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Ann Oncol. 2025 Apr; 36 (4):426-443 Epub 2024 Dec 18
    View PubMed
  3. Malone CD, Bajaj S, He A, Mody K, Hickey R, Sarwar A, Krishnan S, Patel TC, Toskich BB. Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy. J Vasc Interv Radiol. 2025 Mar; 36 (3):414-424.e2 Epub 2024 Nov 23
    View PubMed
  4. Barzi A, Weipert CM, Espenschied CR, Raymond VM, Wang-Gillam A, Nezami MA, Gordon EJ, Mahadevan D, Mody K. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition. Front Oncol. 2024; 14:1339302 Epub 2024 Feb 08
    View PubMed
  5. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Future Oncol 2023 Dec; 19 (38):2505-2516 Epub 2023 Sept 06
    View PubMed
  6. Pappas L, Baiev I, Reyes S, Bocobo AG, Jain A, Spencer K, Le TM, Rahma OE, Maurer J, Stanton J, Zhang K, De Armas AD, Deleon TT, Roth M, Peters MLB, Zhu AX, Boyhen K, VanCott C, Patel T, Roberts LR, Lindsey S, Horick N, Lennerz JK, Iafrate AJ, Goff LW, Mody K, Borad MJ, Shroff RT, Javle MM, Kelley RK, Goyal L. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO Precis Oncol. 2023 Aug; 7:e2200594
    View PubMed
  7. Greenhawt M, Dribin TE, Abrams EM, Shaker M, Chu DK, Golden DBK, Akin C, Anagnostou A, ALMuhizi F, Alqurashi W, Arkwright P, Baldwin JL, Banerji A, Begin P, Ben-Shoshan M, Bernstein J, Bingemann TA, Bindslev-Jensen C, Blumenthal K, Byrne A, Cahill J, Cameron S, Campbell D, Campbell R, Cavender M, Chan ES, Chinthrajah S, Comberiati P, Eastman JJ, Ellis AK, Fleischer DM, Fox A, Frischmeyer-Guerrerio PA, Gagnon R, Garvey LH, Grayson MH, Isabwe GAC, Hartog N, Hendron D, Horner CC, Hourihane JO, Iglesia E, Kan M, Kaplan B, Katelaris CH, Kim H, Kelso JM, Khan DA, Lang D, Ledford D, Levin M, Lieberman JA, Loh R, Mack DP, Mazer B, Mody K, Mosnaim G, Munblit D, Mustafa SS, Nanda A, Nathan R, Oppenheimer J, Otani IM, Park M, Pawankar R, Perrett KP, Peter J, Phillips EJ, Picard M, Pitlick M, Ramsey A, Rasmussen TH, Rathkopf MM, Reddy H, Robertson K, Rodriguez Del Rio P, Sample S, Sheshadri A, Sheik J, Sindher SB, Spergel JM, Stone CA, Stukus D, Tang MLK, Tracy JM, Turner PJ, Vander Leek TK, Wallace DV, Wang J, Wasserman S, Weldon D, Wolfson AR, Worm M, Yacoub MR. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach. J Allergy Clin Immunol. 2023 Aug; 152 (2):309-325 Epub 2023 June 07
    View PubMed
  8. Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023 Jul 6; 115 (7):870-880
    View PubMed
  9. Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, Soong J, McCormick D, Tse E, O'Brien D, Bayat A, Ahn D, Davis SL, Park JO, Oh DY. Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology. 2023 Mar 1; 77 (3):760-773 Epub 2023 Feb 17
    View PubMed
  10. Danese MD, Mody K, Thota R, Lindsey SC, Bachini M, Abdel-Wahab R, Audhuy F, Duryea J, Bobiak S. Treatment Patterns and Survival in Locally Advanced or Metastatic Biliary Tract Cancer Using SEER Medicare Data. Gastro Hep Adv. 2023; 2 (4):580-587 Epub 2023 Jan 21
    View PubMed
  11. Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Expert Opin Pharmacother. 2022 Dec; 23 (18):2079-2089 Epub 2022 Nov 28
    View PubMed
  12. Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Uson Junior PLS, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol. 2022 Dec; 33 (12):1269-1283 Epub 2022 Sept 09
    View PubMed
  13. Franses JW, Lim M, Burgoyne AM, Mody K, Lennerz J, Chang J, Imperial R, Dybel SN, Dinh TM, Masannat J, Weipert CM, Hsiehchen D. Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma. Oncologist. 2022 Nov 3; 27 (11):e908-e911
    View PubMed
  14. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022 Aug; 1 (8):EVIDoa2100070 Epub 2022 June 06
    View PubMed
  15. De la Garza-Ramos C, Montazeri SA, Croome KP, LeGout JD, Sella DM, Cleary S, Burns J, Mathur AK, Overfield CJ, Frey GT, Lewis AR, Paz-Fumagalli R, Ritchie CA, McKinney JM, Mody K, Patel T, Devcic Z, Toskich BB. Radiation Segmentectomy for the Treatment of Solitary Hepatocellular Carcinoma: Outcomes Compared with Those of Surgical Resection. J Vasc Interv Radiol. 2022 Jul; 33 (7):775-785.e2 Epub 2022 Mar 26
    View PubMed
  16. Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, Lau D, Lesinski GB, Yarchoan M. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precis Oncol. 2022 Jun; 6:e2100510
    View PubMed
  17. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
  18. Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, Mody K, Moreno-Aspitia A, Swift MD, Virk A, Bharucha AE, Marquez CP, Patel TC, Gores GJ, Knutson KL. Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clin Proc Innov Qual Outcomes. 2022 Apr; 6 (2):120-125 Epub 2021 Dec 13
    View PubMed
  19. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
  20. Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets. 2022 Jan; 26 (1):79-92 Epub 2022 Jan 24
    View PubMed
  21. Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol. 2022 Jan; 6:e2100156
    View PubMed
  22. Karime C, Wang J, Woodhead G, Mody K, Hennemeyer CT, Borad MJ, Mahadevan D, Chandana SR, Babiker H. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs. 2022 Jan; 31 (1):1-13 Epub 2021 Dec 28
    View PubMed
  23. Mody K, Babiker H, Borad M, Arvind R. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment, New Practice Updates Critical Reviews in Oncology / Hematology Critical Reviews in Oncology/Hematology. 2021.
  24. Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021 Dec; 10 (12):1550-1563 Epub 2021 Nov 20
    View PubMed
  25. Arvind R, Chandana SR, Borad MJ, Pennington D, Mody K, Babiker H. Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. Crit Rev Oncol Hematol. 2021 Dec; 168:103535 Epub 2021 Nov 19
    View PubMed
  26. Paz-Fumagalli R, Core J, Padula C, Montazeri S, McKinney J, Frey G, Devcic Z, Lewis A, Ritchie C, Mody K, Krishnan S, Toskich B. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021 Sep 28; 12 (20):2075-2088 Epub 2021 Sept 28
    View PubMed
  27. Karl Brendel, Tanios Bekaii-Saab, Patrick Boland, Farshid Dayyani, Andrew Dean, Teresa Macarulla, Fiona Maxwell, Kabir Mody, Anna Pedret-Dunn, Zev A. Wainberg, Bin Zhang and. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer and Exposure-Safety Analyses in Patients With Metastatic Pancreatic Cancer American Society for Clinical Pharmacology and Therapeutics. 2021.
  28. Ueberroth BE, Liu AJ, Graham RP, Bekaii-Saab TS, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. Pancreas. 2021 Aug 1; 50 (7):952-956
    View PubMed
  29. Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs. 2021 Aug; 39 (4):1072-1080 Epub 2021 Mar 01
    View PubMed
  30. Liu Y, Raimondo M, Wallace MB, Mody K, Stauffer JA, Zhang L, Ji B, Bi Y. Exome Sequencing of Pancreatic Acinar Carcinoma Identified Distinctive Mutation Patterns. Pancreas. 2021 Aug 1; 50 (7):1007-1013
    View PubMed
  31. Liou H, Mody K, Boyle AW, Keaveny AP, Croome KP, Burns JM, Harnois DM, Patel TC, Toskich B. Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive HCC Resulting in Complete Pathologic Response. Hepatology. 2021 Jul; 74 (1):525-527 Epub 2021 Apr 27
    View PubMed
  32. Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021 Jul; 151:14-24 Epub 2021 May 04
    View PubMed
  33. Li X, Montazeri SA, Paz-Fumagalli R, Padula CA, Wang W, Mody K, Roberts LR, Patel T, Krishnan S, Toskich B. Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres. Eur J Nucl Med Mol Imaging. 2021 Jul; 48(8):2624-2634. Epub 2021 Jan 13.
    View PubMed
  34. Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist. 2021 Jul; 26 (7):569-578 Epub 2021 Mar 05
    View PubMed
  35. Oman SP, Corral JE, Stauffer J, Raimondo M, Mody K, Wallace M. The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004-2013: A SEER Analysis. Cancer Invest. 2021 Mar; 39 (3):229-234 Epub 2021 Feb 18
    View PubMed
  36. Agresti N, Lalezari JP, Amodeo PP, Mody K, Mosher SF, Seethamraju H, Kelly SA, Pourhassan NZ, Sudduth CD, Bovinet C, ElSharkawi AE, Patterson BK, Stephen R, Sacha JB, Wu HL, Gross SA, Dhody K. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. J Transl Autoimmun. 2021; 4:100083 Epub 2021 Jan 06
    View PubMed
  37. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
    View PubMed
  38. Abousaida B, Seneviratne D, Hoppe BS, Ko SJ, Asaithamby A, Cucinotta FA, Kirwan JM, Mody K, Toskich B, Ashman JB, Hallemeier CL, Krishnan S. Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1169-1179 Epub 2021 Sept 24
    View PubMed
  39. Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, Bekaii-Saab TS. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol. 2021; 11:794009 Epub 2022 Jan 10
    View PubMed
  40. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1; 6 (12):e204930 Epub 2020 Dec 10
    View PubMed
  41. Rodriguez-Matta E, Hemmerich A, Starr J, Mody K, Severson EA, Colon-Otero G. Molecular genetic changes in solid pseudopapillary neoplasms (SPN) of the pancreas. Acta Oncol 2020 Sep; 59 (9):1024-1027 Epub 2020 July 16
    View PubMed
  42. Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, Kouchakji E, Rocha F, Carrier E. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020 Aug; 5 (4)
    View PubMed
  43. Azar A, Devcic Z, Paz-Fumagalli R, Vidal LLC, McKinney JM, Frey G, Lewis AR, Ritchie C, Starr JS, Mody K, Toskich B. Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres. J Gastrointest Oncol. 2020 Aug; 11 (4):715-723
    View PubMed
  44. Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Shaib WL. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget. 2020 May 12; 11 (19):1749-1757
    View PubMed
  45. Antwi SO, Li Z, Mody K, Roberts LR, Patel T. Independent and Joint Use of Statins and Metformin by Elderly Patients With Diabetes and Overall Survival Following HCC Diagnosis. J Clin Gastroenterol. 2020 May/Jun; 54 (5):468-476
    View PubMed
  46. Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020 Mar 1; 6 (3):e194489 Epub 2020 Mar 12
    View PubMed
  47. Mizrahi JD, Gunchick V, Mody K, Xiao L, Surapaneni P, Shroff RT, Sahai V. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World J Gastrointest Oncol. 2020 Jan 15; 12 (1):83-91
    View PubMed
  48. Kroner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc. 2019 Dec; 90 (6):881-892 Epub 2019 Sept 14
    View PubMed
  49. Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019 Dec 1; 25 (23):7035-7045 Epub 2019 Aug 04
    View PubMed
  50. Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019 Dec; 10 (6):1099-1109
    View PubMed
  51. Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. JCO Precis Oncol. 2019 Dec; 3:1-9
    View PubMed
  52. Madamsetty VS, Pal K, Dutta SK, Wang E, Thompson JR, Banerjee RK, Caulfield TR, Mody K, Yen Y, Mukhopadhyay D, Huang HS. Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. Bioconjug Chem. 2019 Oct 16; 30 (10):2703-2713 Epub 2019 Oct 04
    View PubMed
  53. Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol. 2019 Oct; 36 (4):287-297 Epub 2019 Oct 31
    View PubMed
  54. Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, Bekaii-Saab T. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Oncologist. 2019 Sep; 24 (9):1174-1179 Epub 2019 June 04
    View PubMed
  55. Bailey RE, Surapaneni PK, Core J, Vidal LLC, LeGout J, Ritchie C, Frey G, McKinney JM, Sella D, Paz-Fumagalli R, Toskich B, Mody K. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. J Gastrointest Oncol. 2019 Aug; 10(4):688-694.
    View PubMed
  56. Mody K, Kasi PM, Yang JD, Surapaneni PK, Ritter A, Roberts A, Nagy R, Borad MJ. Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. J Gastrointest Oncol. 2019 Aug; 10 (4):745-750
    View PubMed
  57. Mody K, Mansfield AS, Vemireddy L, Nygren P, Gulbo J, Borad M. A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. Invest New Drugs. 2019 Aug; 37 (4):684-692 Epub 2018 Nov 21
    View PubMed
  58. Iqbal M, Roberts A, Starr J, Mody K, Kasi PM. Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. J Gastrointest Oncol. 2019 Jun; 10 (3):400-406
    View PubMed
  59. Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019 Jun; 10(3):554-561.
    View PubMed
  60. Pope ED 3rd, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA 3rd, Mody K. Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin Ther Targets. 2019 Jun; 23 (6):473-483 Epub 2019 May 10
    View PubMed
  61. Mody K, Kasi PM, Yang JD, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating tumor dna profiling of advanced biliary tract cancers JCO Precision Oncology. 2019 Mar 18; 3
  62. Mody K, Abou-Alfa GK. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Curr Treat Options Oncol. 2019 Jan 11; 20 (2):3
    View PubMed
  63. Kasi PM, Maige CL, Shahjehan F, Rodgers JM, Aloszka DL, Ritter A, Andrus ML, Mcmillan JM, Mody K, Sharma A, Jain MK. A Care Process Model to Deliver (177)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. Front Oncol. 2018; 8:663 Epub 2019 Jan 09
    View PubMed
  64. Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, Bekaii-Saab T. A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. J Gastrointest Oncol. 2018 Dec; 9 (6):1063-1073
    View PubMed
  65. Pelt J, Busatto S, Ferrari M, Thompson EA, Mody K, Wolfram J. Chloroquine and nanoparticle drug delivery: A promising combination. Pharmacol Ther. 2018 Nov; 191:43-49. Epub 2018 Jun 20.
    View PubMed
  66. Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic Therapy in Colorectal Cancer. Cancer J. 2018 Jul/Aug; 24 (4):165-170
    View PubMed
  67. Mody K, Bekaii-Saab T. Clinical Trials and Progress in Metastatic Colon Cancer. Surg Oncol Clin N Am. 2018 Apr; 27 (2):349-365
    View PubMed
  68. Kandel P, Wallace MB, Stauffer J, Bolan C, Raimondo M, Woodward TA, Gomez V, Ritter AW, Asbun H, Mody K. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. J Pancreat Cancer. 2018; 4 (1):88-94 Epub 2018 Nov 01
    View PubMed
  69. Mody K, Cleary SP. A Review of Circulating Tumor DNA in Hepatobiliary Malignancies. Front Oncol. 2018; 8:212 Epub 2018 June 11
    View PubMed
  70. Baldeo C, Vishnu P, Mody K, Kasi PM. Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications. SAGE Open Med Case Rep. 2018; 6:2050313X18786405 Epub 2018 July 04
    View PubMed
  71. Kabir, Bekaii-Saab Tanios. Optimizing Sequencing Beyond Disease Progression After Second-Line Therapy in Metastatic Colorectal Cancer American Journal of Hematology/Oncology.2017;
  72. Stauffer JA, Coppola A, Villacreses D, Mody K, Johnson E, Li Z, Asbun HJ. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Surg Endosc. 2017 May; 31 (5):2233-2241 Epub 2016 Sept 07
    View PubMed
  73. Elias AW, Kasi PM, Stauffer JA, Thiel DD, Colibaseanu DT, Mody K, Joseph RW, Bagaria SP. The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Front Oncol. 2017; 7:121 Epub 2017 June 12
    View PubMed
  74. Stauffer JA, Coppola A, Mody K, Asbun HJ. Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma. World J Surg. 2016 Jun; 40 (6):1477-84
    View PubMed
  75. Hammond WA, Crozier JA, Nakhleh RE, Mody K. Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon. J Gastrointest Oncol. 2016 Apr; 7 (2):E22-4
    View PubMed
  76. Shatzel J, Kim J, Sampath K, Syed S, Saad J, Hussain ZH, Mody K, Pipas JM, Gordon S, Gardner T, Rothstein RI. Drug eluting biliary stents to decrease stent failure rates: A review of the literature. World J Gastrointest Endosc. 2016 Jan 25; 8 (2):77-85
    View PubMed
  77. Mody K, Feldman Rebecca, Reddy Sandeep K., Reynolds GA, Mcmillan JM, Johnson EA. PD-1/PD-L1 expression and molecular associations in HPB malignancies. Journal of Clinical Oncology.2016;34:(suppl 4S)Abstr 289.
  78. Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016 Jan; 8 (1):57-84
    View PubMed
  79. Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, Tsongalis GJ, Suriawinata AA. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol. 2015 Oct; 99(2):240-4. Epub 2015 Jul 17.
    View PubMed
  80. Gardner TB, Hessami N, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Zaki B, Tsapakos MJ, Suriawinata AA, Putra J, Tsongalis GJ, Mody K, Gordon SR, Pipas JM. The Effect of Neoadjuvant Chemoradiation on Pancreatic Cancer-Associated Diabetes Mellitus. Pancreas. 2014 Jul 03.
    View PubMed
  81. Liu X, Mody K, de Abreu FB, Pipas JM, Peterson JD, Gallagher TL, Suriawinata AA, Ripple GH, Hourdequin KC, Smith KD, Barth RJ Jr, Colacchio TA, Tsapakos MJ, Zaki BI, Gardner TB, Gordon SR, Amos CI, Wells WA, Tsongalis GJ. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem. 2014 Jul; 60(7):1004-11. Epub 2014 May 12.
    View PubMed
  82. Mody K, Wallace JS, Stearns DM, Bowers G, Lacy SR, Levy NB, Zug KA, Lansigan F. CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):319-23. Epub 2013 Jan 10.
    View PubMed
  83. Mody K, Strauss E, Lincer R, Frank RC. Complete Response in Gallbladder Cancer to Erlotinib Plus Gemcitabine Does Not Require Mutation of the Epidermal Growth Factor Receptor Gene: A Case Report. BMC Cancer. 2010; 10:570.